BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo MR, Di Meo I, Polito R, Auriemma MC, Gambardella A, di Mauro G, Capuano A, Paolisso G. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacol Res 2022;176:106062. [PMID: 35017046 DOI: 10.1016/j.phrs.2022.106062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Pang B, Zhang LL, Li B, Sun FX, Wang ZD. The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation. Physiol Behav 2023;263:114134. [PMID: 36809844 DOI: 10.1016/j.physbeh.2023.114134] [Reference Citation Analysis]
2 Piątkowska-Chmiel I, Herbet M, Gawrońska-Grzywacz M, Pawłowski K, Ostrowska-Leśko M, Dudka J. Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacology (Berl) 2023;240:983-1000. [PMID: 36869919 DOI: 10.1007/s00213-023-06341-7] [Reference Citation Analysis]
3 Scheen AJ, Bonnet F. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance? Diabetes Metab 2023;49:101419. [PMID: 36640828 DOI: 10.1016/j.diabet.2023.101419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Tang H, Shao H, Shaaban CE, Yang K, Brown J, Anton S, Wu Y, Bress A, Donahoo WT, DeKosky ST, Bian J, Guo J. Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies. J Am Geriatr Soc 2023. [PMID: 36821780 DOI: 10.1111/jgs.18306] [Reference Citation Analysis]
5 Ezkurdia A, Ramírez MJ, Solas M. Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance. Int J Mol Sci 2023;24. [PMID: 36901787 DOI: 10.3390/ijms24054354] [Reference Citation Analysis]
6 Donniacuo M, De Angelis A, Telesca M, Bellocchio G, Riemma MA, Paolisso P, Scisciola L, Cianflone E, Torella D, Castaldo G, Capuano A, Urbanek K, Berrino L, Rossi F, Cappetta D. Atrial fibrillation: Epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors. Pharmacol Res 2023;188:106591. [PMID: 36502999 DOI: 10.1016/j.phrs.2022.106591] [Reference Citation Analysis]
7 Dao L, Choi S, Freeby M. Type 2 diabetes mellitus and cognitive function: understanding the connections. Curr Opin Endocrinol Diabetes Obes 2023;30:7-13. [PMID: 36385094 DOI: 10.1097/MED.0000000000000783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wu CY, Iskander C, Wang C, Xiong LY, Shah BR, Edwards JD, Kapral MK, Herrmann N, Lanctôt KL, Masellis M, Swartz RH, Cogo-Moreira H, MacIntosh BJ, Rabin JS, Black SE, Saskin R, Swardfager W. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study. Diabetes Care 2023;46:297-304. [PMID: 36508692 DOI: 10.2337/dc22-1705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Amin AM, Mostafa H, Khojah HMJ. Insulin resistance in Alzheimer's disease: The genetics and metabolomics links. Clin Chim Acta 2023;539:215-36. [PMID: 36566957 DOI: 10.1016/j.cca.2022.12.016] [Reference Citation Analysis]
10 Li ZH, Jiang YY, Long CY, Peng Q, Yue RS. The gut microbiota-astrocyte axis: Implications for type 2 diabetic cognitive dysfunction. CNS Neurosci Ther 2023. [PMID: 36601656 DOI: 10.1111/cns.14077] [Reference Citation Analysis]
11 Wang M, Guan X, Yan J, Michael N, Liu X, Tan R, Lv X, Yan F, Cao Y. Perceptions and responses to cognitive decline in people with diabetes: A systematic review of qualitative studies. Front Public Health 2023;11:1076030. [PMID: 36875353 DOI: 10.3389/fpubh.2023.1076030] [Reference Citation Analysis]
12 Chen J, Liu Y, Zhou K, Zhang W, Wen B, Xu K, Liu Y, Chen L, Huang Y, He B, Hang W, Chen J. DISC1 inhibits GSK3β activity to prevent tau hyperphosphorylation under diabetic encephalopathy. Biofactors 2023;49:173-84. [PMID: 36070513 DOI: 10.1002/biof.1884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wu C, Wang W, Cheng S, Zhang Y, Li L, Zhang L, Chen N, Du J, Ren L, Lang H. The relationship between components of hypoglycemia worries and avoiding hypoglycemia behavior in type 2 diabetes mellitus with hypoglycemia: a network analysis.. [DOI: 10.21203/rs.3.rs-2363421/v1] [Reference Citation Analysis]
14 Hsu SJ, Huang HC, Pun CK, Chang CC, Chuang CL, Huang YH, Hou MC, Lee FY. Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats. J Pharmacol Exp Ther 2022;383:25-31. [PMID: 35926870 DOI: 10.1124/jpet.122.001289] [Reference Citation Analysis]
15 Canna A, Esposito F, Tedeschi G, Trojsi F, Passaniti C, di Meo I, Polito R, Maiorino MI, Paolisso G, Cirillo M, Rizzo MR. Neurovascular coupling in patients with type 2 diabetes mellitus. Front Aging Neurosci 2022;14:976340. [DOI: 10.3389/fnagi.2022.976340] [Reference Citation Analysis]
16 Wu CY, Shapiro L, Ouk M, MacIntosh BJ, Black SE, Shah BR, Swardfager W. Glucose-lowering drugs, cognition, and dementia: The clinical evidence. Neurosci Biobehav Rev 2022;137:104654. [PMID: 35398114 DOI: 10.1016/j.neubiorev.2022.104654] [Reference Citation Analysis]
17 Zhu Y, Liu Q, Zhu Y, Guo T, Jin M, Hao J, Qi C, Miao X, Xi D, Fan J, Li J. Effects of Common Myokines on Diabetes Mellitus. JDM 2022;12:153-166. [DOI: 10.4236/jdm.2022.123013] [Reference Citation Analysis]